Literature DB >> 9448006

The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.

M Alcalay1, L Tomassoni, E Colombo, S Stoldt, F Grignani, M Fagioli, L Szekely, K Helin, P G Pelicci.   

Abstract

PML is a nuclear protein with growth-suppressive properties originally identified in the context of the PML-retinoic acid receptor alpha (RAR alpha) fusion protein of acute promyelocytic leukemia. PML localizes within distinct nuclear structures, called nuclear bodies, which are disrupted by the expression of PML-RAR alpha. We report that PML colocalizes with the nonphosphorylated fraction of the retinoblastoma protein (pRB) within nuclear bodies and that pRB is delocalized by PML-RAR alpha expression. Both PML and PML-RAR alpha form complexes with the nonphosphorylated form of pRB in vivo, and they interact with the pocket region of pRB. The regions of PML and PML-RAR alpha involved in pRB binding differ; in fact, the B boxes and the C-terminal region of PML, the latter of which is not present in PML-RAR alpha, are essential for the formation of stable complexes with pRB. Functionally, PML abolishes activation of glucocorticoid receptor-regulated transcription by pRB, whereas PML-RAR alpha further increases it. Our results suggest that PML may be part of transcription-regulatory complexes and that the oncogenic potential of the PML-RAR alpha protein may derive from the alteration of PML-regulated transcription.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448006      PMCID: PMC108821          DOI: 10.1128/MCB.18.2.1084

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  The acute promyelocytic leukaemia-associated PML gene is induced by interferon.

Authors:  C Lavau; A Marchio; M Fagioli; J Jansen; B Falini; P Lebon; F Grosveld; P P Pandolfi; P G Pelicci; A Dejean
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

2.  Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.

Authors:  F Grignani; U Testa; D Rogaia; P F Ferrucci; P Samoggia; A Pinto; D Aldinucci; V Gelmetti; M Fagioli; M Alcalay; J Seeler; F Grignani; I Nicoletti; C Peschle; P G Pelicci
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

Review 3.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

4.  Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.

Authors:  J L Grisolano; R L Wesselschmidt; P G Pelicci; T J Ley
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

5.  The glucocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors.

Authors:  O Wessely; E M Deiner; H Beug; M von Lindern
Journal:  EMBO J       Date:  1997-01-15       Impact factor: 11.598

6.  Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs.

Authors:  P L Chen; D J Riley; Y Chen; W H Lee
Journal:  Genes Dev       Date:  1996-11-01       Impact factor: 11.361

7.  A role for retinoblastoma protein in potentiating transcriptional activation by the glucocorticoid receptor.

Authors:  P Singh; J Coe; W Hong
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

8.  Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia.

Authors:  L Flenghi; M Fagioli; L Tomassoni; S Pileri; M Gambacorta; R Pacini; F Grignani; T Casini; P F Ferrucci; M F Martelli
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

9.  The PML gene encodes a phosphoprotein associated with the nuclear matrix.

Authors:  K S Chang; Y H Fan; M Andreeff; J Liu; Z M Mu
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

10.  PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu.

Authors:  J H Liu; Z M Mu; K S Chang
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  47 in total

1.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

3.  Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein.

Authors:  S Tsuzuki; M Towatari; H Saito; T Enver
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2.

Authors:  Satoshi Tashiro; Akihiko Muto; Keiji Tanimoto; Haruka Tsuchiya; Hiroshi Suzuki; Hideto Hoshino; Minoru Yoshida; Joachim Walter; Kazuhiko Igarashi
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

5.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

6.  PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.

Authors:  T Regad; A Saib; V Lallemand-Breitenbach; P P Pandolfi; H de Thé; M K Chelbi-Alix
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

7.  The tumor suppressor Pml regulates cell fate in the developing neocortex.

Authors:  Tarik Regad; Cristian Bellodi; Pierluigi Nicotera; Paolo Salomoni
Journal:  Nat Neurosci       Date:  2009-01-11       Impact factor: 24.884

8.  SUMO conjugation to the matrix attachment region-binding protein, special AT-rich sequence-binding protein-1 (SATB1), targets SATB1 to promyelocytic nuclear bodies where it undergoes caspase cleavage.

Authors:  Joseph-Anthony T Tan; Yujie Sun; Jing Song; Yuan Chen; Theodore G Krontiris; Linda K Durrin
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

9.  Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.

Authors:  Eunsil Yu; Eun Kyung Choi; Chong Jai Kim
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

10.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.